Dr. Lilly Xu Appointed as Chief Technology Officer of Medicilon to Drive Innovation

Medicilon Welcomes Dr. Lilly Xu as CTO

Medicilon, a leading contract research organization (CRO) specializing in preclinical development, has officially appointed Dr. Lilly Xu as its new Chief Technology Officer (CTO). This strategic move aims to bolster technological innovations and global expansions at the company, enhancing Medicilon's ability to provide top-tier research and development solutions.

Extensive Experience in Drug Development

Dr. Xu brings over 30 years of experience in the pharmaceutical and biotechnology sectors. A graduate with a Ph.D. in biology from the University of St. Louis, she is well-regarded for her expertise in pharmacokinetics, toxicology, and drug metabolism. During her career, Dr. Xu has successfully led numerous global drug development programs, guiding them from early discovery through clinical stages. Her previous managerial roles include positions at prominent pharmaceutical companies such as Pharmaron, Icagen, Purdue Pharma, Sanofi, and Amgen.

Dr. Chunlin Chen, founder and CEO of Medicilon, expressed that the company is thrilled to welcome Dr. Xu during this vital growth phase. He highlighted how her extensive knowledge and global perspective align with Medicilon's vision for innovation and international presence.

Commitment to Innovation and Advancement

In her own words, Dr. Xu shared her excitement about joining Medicilon, stating, "It is an honor to join a forward-thinking team. I look forward to contributing to platform innovations, accelerating research into clinical breakthroughs, and achieving milestones that benefit our clients and their patients around the world."

Medicilon continues to strengthen its advanced research platforms, which include nucleic acids, antibody-drug conjugates (ADCs), PROTAC therapies, antibodies, as well as cell and gene therapies. These initiatives are critical to maintaining the company’s leadership position in preclinical drug development.

Building a Global Presence

As Medicilon embarks on this new chapter under Dr. Xu’s leadership, the company is poised to enhance its service offerings and increase its competitive edge within the industry. The integration of innovative technologies and expanded capabilities will allow Medicilon to better serve its clients and contribute more significantly to global health advancements.

With a firm commitment to excellence and a focus on groundbreaking advancements in drug development, Medicilon aims to solidify its standing as a premier provider of preclinical research solutions. As the company progresses into this new phase, the leadership of Dr. Lilly Xu is expected to inspire further achievements and foster a culture of innovation.